Using bone marrow biomarkers to predict recurrence in triple negative breast cancer
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
This study is looking at how certain markers in the bone marrow of people with triple negative breast cancer can help doctors understand who might face a higher chance of their cancer coming back, so they can find better treatments for those patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10915473 on NIH RePORTER |
What this research studies
This research investigates how specific biomarkers in the bone marrow of patients with triple negative breast cancer (TNBC) can help predict the likelihood of cancer recurrence. The study focuses on disseminated tumor cells (DTCs) and the immune environment in the bone marrow, which may influence treatment resistance and metastatic potential. By analyzing bone marrow specimens from TNBC patients, the researchers aim to identify gene expression patterns that indicate which patients might benefit from immunotherapy. The goal is to improve treatment strategies and outcomes for patients at risk of recurrence.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have undergone or are undergoing treatment.
Not a fit: Patients with non-triple negative breast cancer or those who are not currently receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans that effectively prevent cancer recurrence in TNBC patients.
How similar studies have performed: Other research has shown promise in using biomarkers to predict cancer outcomes, suggesting that this approach could be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Aft, Rebecca L. — Washington University
- Study coordinator: Aft, Rebecca L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.